Articles tagged with Cancer Patients
The NCCN 2024 Annual Conference shared updates on improving cancer care worldwide, including plenary sessions on drug shortages and hereditary cancer risk. Key takeaways include the need for transparency around oncology supply chains and the importance of genetic testing to reduce cancer risk.
A new study found that survival rates after hip or spine fractures are comparable to or worse than those seen in patients with certain types of cancer. The study, which analyzed data from over 100,000 Canadians aged 65 and older, highlights the urgent need for secondary prevention interventions before hospital discharge.
A study of 12 patients with sinonasal mucosal melanoma found that brisk tumor-infiltrating lymphocytes associated with improved outcomes, while anti-PD-L1 therapy showed potential as a therapeutic strategy. Further research is needed to confirm these findings.
A 10-minute virtual reality session significantly lessened pain in hospitalized patients with cancer, with sustained benefits even a day later. The study found that VR sessions had a greater impact than guided imagery, improving not only pain severity but also related issues like general distress.
A pilot study by UCLA Health investigators suggests that treating patients with immunotherapy and chemotherapy before surgery may improve long-term outcomes for those with borderline resectable pancreatic cancer. The study found a higher rate of successful tumor removal and increased overall survival when compared to historical controls.
A phase 2 study by Dana-Farber Cancer Institute investigators found notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer, including six out of 16 patients experiencing tumor reduction. The combination of mirvetuximab soravtansine and pembrolizumab met its primary endpoint and showed promise for ...
MD Anderson researchers presented studies on combination therapies for AML and lung cancer, tumor microbiomes in immunity, and improved HPV screening. Genetic markers predict extended survival with KRAS inhibitors and may identify patients who benefit from novel combinations.
A large trial enrolling nearly 2,800 patients from five countries has clarified the situation for patients with larger metastases. The study found that leaving most of the lymph nodes intact resulted in similar recurrence rates as completion axillary dissection, but with fewer arm-related complications.
Researchers at the University of Cincinnati Cancer Center presented abstracts on new potential drugs and targets for treating various types of cancer. A study found that a brain-permeable drug called AM-101 sensitizes brain metastatic tumors to radiation, improving survival in preclinical animal models.
A new study by Fred Hutchinson Cancer Center found that 21.9% of people with cancer participate in some form of clinical research, including treatment trials and biorepository studies. Enrollment in treatment trials was particularly high at National Cancer Institute-designated centers.
A Northwestern University study found ChatGPT's responses to radiation oncology patient questions were on par or exceeded professional society answers. The AI technology aims to empower patients before and after seeing physicians, while also reducing clinician burnout.
Researchers from the University of Southern Denmark have identified specific groups of cells driving resistance to chemotherapy in TNBC, offering new biomarkers and alternative treatment options. The studies shed light on the mechanisms behind chemoresistance and its epigenetic control.
A 10-center study found that microwave ablation is associated with similar progression-free survival rates to surgery but with fewer complications and a greater potential for preserving thyroid function. The procedure resulted in less blood loss, shorter incision length, and shorter procedure and hospitalization durations.
Researchers at Tel Aviv University developed a novel therapeutic strategy using existing medications to inhibit bone metastasis in breast cancer patients. The combination of drugs improved survival rates and reduced bone metastases in animal models and human tissue samples.
Researchers developed a novel assay to study immune checkpoint molecules in blood plasma, finding elevated concentrations in patients with immune-reactive tumors who were nonresponsive to PD-1/PD-L1 blockade therapy. Soluble factors correlated with exhausted antitumor immunity and predicted therapy efficacy.
A second-generation melanoma vaccine has shown improved survival rates for male patients compared to female patients, particularly those who are younger and have earlier-stage cancer. The vaccine targets helper T cells to recognize melanoma proteins, leading to boosted patient survival and reduced cancer reoccurrences.
A survey of 204 oncologists found that while patients should understand AI models, most agreed that patients should consent to their use. The study highlights the need for rigorous assessments of AI's impact on care decisions and patient autonomy.
A clinical trial from Keck Medicine of USC will investigate the feasibility of treating non-small cell lung cancer with immunotherapy provided at home. The study aims to enroll 37 patients and examine the safety, efficacy, and patient compliance with at-home treatment.
A nationwide study finds that individuals diagnosed with colon cancer who resided in previously redlined neighborhoods are more likely to be diagnosed with advanced-stage disease and have worse survival rates. The research highlights the long-lasting impact of institutional racism on access to quality cancer care.
A study published in the Journal of the American College of Surgeons found that hospitals accredited by the National Accreditation Program for Rectal Cancer (NAPRC) demonstrate significantly better outcomes for patients undergoing rectal cancer surgery. These institutions show lower rates of mortality, complications, and morbidity comp...
The study found that neoadjuvant chemotherapy increased median overall survival to 37 months and progression-free survival to 26 months. 57.2% of patients showed an objective response, with nearly one-fourth experiencing lymph-node pathologic complete response.
Researchers have identified a protein, NPEPPS, that enables cisplatin-resistant cancer cells to become responsive to treatment. This discovery could increase patient eligibility and make platinum-based therapies more effective.
Researchers assessed the feasibility of dual PD-L1/CTLA-4 checkpoint inhibition in Stage II or III hormone receptor-positive, HER2-negative breast cancer. Eight patients received upfront durvalumab and tremelimumab prior to neoadjuvant chemotherapy, showing mixed responses and limited benefit.
A new therapy combines gene-modified dendritic cells with immunotherapy to promote a stronger immune response against lung cancer. The treatment slows down tumor growth and activates T cells to attack cancer cells systemically.
A new analysis by researchers from Penn Medicine found that minority patients with lymphoma may be less likely to receive CAR T cell therapy due to clinical, provider, and socioeconomic barriers. The study assessed data from two cancer centers and found significant disparities in treatment access among minority populations.
Researchers present findings on immunotherapy approaches, a potential biomarker for neuroendocrine carcinomas, and improved treatments for pancreatic cancer and melanoma. A UCLA team identified UCHL1 as a molecular indicator and therapeutic target for aggressive neuroendocrine cancers.
The COVID-19 pandemic caused a significant decrease in colorectal cancer surgeries, with patients undergoing procedures having more advanced stages of cancer compared to those treated in 2019. The study found that approximately 10,000 fewer patients did not have surgery for colorectal cancer in 2020.
Primary care physicians struggle to balance harms and benefits of lung cancer screening in patients with multiple health issues, often relying on clinical judgment. Ultimately, the decision rests with the patient, who makes their own choice despite physician advice.
Researchers found no significant differences between standard and keyhole surgical incision types on short-term clinical outcomes, physical function recovery, or NHS resource costs for oesophageal cancer patients. The ROMIO study suggests that surgeons can maintain their preferred procedure type without compromising patient care.
A new study suggests that tailored treatment can predict the response of breast cancer patients to chemotherapy, allowing for safe omission of extensive lymph node removal. The MARI protocol showed a 95% overall survival rate and 89% disease-free survival rate in patients who achieved pathological complete response.
Researchers found that next-generation sequencing (NGS) identified more patients with microsatellite instability than immunohistochemistry (IHC), potentially leading to thousands of missed diagnoses and patients receiving incorrect treatment. NGS could guide the standard of care towards using this test method instead of IHC.
Researchers have developed a new tool to help clinics recruit patients from more communities by analyzing nearby hospitals serving diverse populations. The approach aims to increase accessibility and diversity in cancer trials, with the potential to improve patient outcomes.
A combined PET-MRI scan improved treatment outcomes for 57 out of 205 patients with early-stage breast cancer. The scan helped doctors spot signs of tumour spread, enabling alternative treatments such as chemotherapy or different surgical approaches.
A new AI tool can predict which breast cancer patients are at risk of chronic arm swelling after surgery and radiotherapy. The tool, developed by international researchers, uses machine learning algorithms to analyze patient data and provides easily understandable explanations for doctors and patients.
Adding ribociclib to hormone therapy improves invasive disease-free survival by 90.4% at three years, distant disease-free survival by 90.8%, and recurrence-free survival by 91.7%. The study found a 25% relative reduction in recurrence rate for patients with stage 2 or 3 HR-positive, HER2-negative early breast cancer.
Researchers have developed a vascularized organoid model (VOM) that accurately replicates the actual vasculature and environment of gastric cancer, enabling patient-specific predictions of response to anticancer drugs. The VOM demonstrates high cell viability rates and similarity to actual gastric cancer conditions.
Researchers found that young breast cancer patients who received a low-dose radiotherapy boost had a lower risk of local recurrence after 10 years, with only 4.4% experiencing recurrence. In contrast, high-dose boosts resulted in fewer recurrences but also more severe fibrosis and cosmetic issues.
A new genetic test has identified patients with triple negative early-stage breast cancer who are unlikely to respond to immunotherapy drugs. The test, called ImPrintTN, can predict a patient's likelihood of responding to these treatments and help avoid severe side effects.
Researchers identify mitochondrial priming as a key driver of multi-drug resistance in relapsed acute myeloid leukemia. A new technique called dynamic BH3 profiling reveals anti-cancer drugs capable of overcoming resistance.
New data show that adding pembrolizumab to chemotherapy before and after surgery for breast cancer leads to better outcomes, with significant increases in pathological complete response rates across all age groups. The study also found similar rates of breast-conserving surgery and mastectomy, as well as lower residual cancer burdens.
A new study from Johns Hopkins Medicine found that circulating tumor DNA levels can accurately assess how gastroesophageal cancers respond to treatment and predict future prognosis. The study tracked minimal residual disease by analyzing ctDNA, showing a correlation between ctDNA clearance and cancer-free survival.
A randomized controlled trial found that exercise programmes reduced fatigue and improved quality of life for patients with metastatic breast cancer. The study showed the greatest benefit among younger patients, but also suggested that supervised exercise can be beneficial for all patients with advanced disease.
Researchers propose combining osimertinib with gefitinib to increase progression-free survival rates in EGFR-mutant lung cancer patients. A comprehensive PC approach could dramatically boost PFS for 80% of patients, eliminating harm and improving treatment outcomes.
The ALEXANDRA/IMpassion030 phase 3 trial found that adding atezolizumab to chemotherapy after surgery did not improve survival for early-stage triple-negative breast cancer patients. Researchers also found no benefit in different sub-groups, such as those with lymph node spread and PD-L1 positive cancer.
A new study found that the COVID-19 pandemic could have led to 20,000 prostate cancer diagnoses being missed in England. The study used data from OpenSAFELY and found a significant drop in diagnosis rates during the pandemic, with a decline of 31% in 2020 and 18% in 2021.
A combination of short-course hormonal therapy and stereotactic body radiation therapy has been shown to be safe and effective in treating metastatic prostate cancer. In a preliminary study, 50% of patients remained recurrence-free six months after treatment, with less than a quarter experiencing severe side effects.
The RUBY Part 2 trial shows significant improvement in progression-free survival for patients with primary advanced or recurrent endometrial cancer treated with dostarlimab. Dostarlimab plus niraparib plus carboplatin/paclitaxel demonstrates a role for PARP inhibitor maintenance in improving patient outcomes.
Research highlights new findings on social vulnerability and survivorship after colorectal cancer resection, as well as disparities in kidney recovery among Black donors. Additionally, studies reveal cost savings from implementing quality interventions and explore eligibility for transplants in obese patients with end-stage renal disease.
Researchers at Mass General Cancer Center have achieved dramatic tumor regression in glioblastoma patients after receiving next generation CAR-T therapy. The treatment, known as INCIPIENT, combines two forms of therapy to target mixed cell populations within tumors.
A research team at the University of Cologne has identified mechanisms governing drug response in small cell lung cancer. The study reveals that large populations of treatment-sensitive cells often hide numerous therapy-resistant cells that can multiply unchecked after successful treatment.
Researchers create a technique using prime editing to quickly and easily screen cancer genes, revealing new information on p53 mutations. The method allows for the analysis of over 1,000 different mutations in the tumor suppressor gene p53, which are seen in more than half of all cancer patients.
A new study from Uppsala University found that women with germ cell tumors have a significantly lower five-year survival rate (85.2%) compared to men (98.2%). The researchers suggest that concentrating patients in fewer hospitals and using treatment strategies for testicular cancer could improve survival rates and reduce side effects.
Researchers at MIT developed GastroShield, a sprayable gel that prevents bleeding and leakage from weakened gastrointestinal tissues during endoscopic procedures. The gel forms a protective layer that reinforces tissue integrity and promotes healing.
A Phase III clinical trial showed that cancer patients who received specialized mental health support experienced lasting improvements in quality of life, reduced pain, depression, and fatigue. The intervention also led to lower risk of cardiovascular disease in family caregivers and substantial cost savings for the healthcare system.
A study found that up to 87% of childhood cancer survivors are not following recommended screening guidelines, leaving them vulnerable to late effects such as heart disease and certain cancers. The lack of awareness and barriers to adherence may contribute to this low rate, highlighting the need for improved support and education.
A Canadian Medical Association Journal study finds that financial distress affects up to 33% of cancer patients in Canada, causing direct, indirect, and emotional costs. The authors suggest supporting home care, improved benefit plans, and pharmacare to alleviate the financial burden on patients and their families.
A novel antibody constant region variant (REW) extends plasma half-life and improves biodistribution, allowing for both invasive and non-invasive delivery. The REW technology also enhances the complement system, providing enhanced ability to kill cancer cells and bacteria.
The NCI-MATCH precision medicine trial discovered that trastuzumab-pertuzumab, approved for HER2-positive breast cancer, can shrink tumors in patients with other types of cancer and high levels of the HER2 gene. The study found a 12% confirmed overall response rate, with partial responses in various cancers.
Researchers analyzed access to new treatments for early-stage lung cancer in Europe, highlighting existing disparities in healthcare systems and reimbursement structures. The study calls for a collective European approach to reduce inequalities in access to care.
A Cancer Research UK-funded study uses AI to identify two distinct subtypes of prostate cancer, termed evotypes, which could lead to personalized treatments. The discovery has the potential to improve diagnosis and treatment outcomes, saving thousands of lives in the future.